Rhenman & Partners Asset Management Ab Incyte Corp Transaction History

Rhenman & Partners Asset Management Ab

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$80.74 - $97.7 $3.23 Million - $3.91 Million	-40,000 Closed	0 $0
Q2 2020 Jul 16, 2020	SELL	$74.18 - $108.93 $741,800 - $1.09 Million	-10,000 Reduced 20.0%	40,000 $4.16 Million
Q1 2020 Apr 16, 2020	SELL	$63.18 - $85.97 $947,700 - $1.29 Million	-15,000 Reduced 23.08%	50,000 $3.66 Million
Q4 2019 Jan 17, 2020	BUY	$73.04 - $95.72 $4.75 Million - $6.22 Million	65,000 New	65,000 $5.68 Million
Q3 2019 Oct 16, 2019	SELL	$72.82 - $86.52 $7.28 Million - $8.65 Million	-100,000 Closed	0 $0

Q1 2019 Apr 11, 2019	SELL	$63.56 - $88.17 $10.6 Million - $14.7 Million	-166,416 Reduced 62.46%	100,000 $8.6 Million
Q4 2018 Feb 05, 2019	SELL	$58.5 - $69.94 $6.46 Million - $7.73 Million	-110,500 Reduced 29.32%	266,416 $16.9 Million
Q3 2018 Oct 03, 2018	SELL	$61.75 - $74.23 $422,802 - $508,252	-6,847 Reduced 1.78%	376,916 $26 Million
Q2 2018 Jul 20, 2018	BUY	$60.85 - $83.98 $13.7 Million - $18.9 Million	224,800 Added 141.42%	383,763 $25.7 Million
Q1 2018 Apr 11, 2018	SELL	$83.06 - $100.98 $393,704 - $478,645	-4,740 Reduced 2.9%	158,963 $13.2 Million
Q4 2017 Jan 19, 2018	BUY	$93.56 - $116.6 $4.56 Million - $5.68 Million	48,703 Added 42.35%	163,703 $15.5 Million
Q3 2017 Oct 13, 2017	BUY	$109.15 - $138.27 $12.6 Million - $15.9 Million	115,000	115,000 $13.4 Million

617

215M

366K

445K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.